Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM001 in healthy preterm and term infants
NCT05630573Phase 2Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TNM001 in respiratory syncytial virus infection (RSV), sponsored by Trinomab Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
TNM001
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05630573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630573.